Related Experiment Video
Updated: Mar 26, 2026
10:41
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
12.4K
[Waldenström's macroglobulinemia. Current developments in diagnostics and therapy]
A Grunenberg1, C Buske2,3
1Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Deutschland.
Der Internist
|February 3, 2016
Summary
Waldenström's macroglobulinemia (WM) is a rare B-cell lymphoma. Genetic subtypes exist, and while rituximab plus chemotherapy is standard, new treatments like ibrutinib offer chemotherapy-free options.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Waldenström's macroglobulinemia (WM) is a rare B-cell lymphoma, accounting for 1-2% of hematological neoplasms.
- Genetic characterization enables the subdivision of WM into distinct genotypes.
- Current treatment mainstays include the combination of rituximab and chemotherapy.
Purpose of the Study:
- To review the current understanding of Waldenström's macroglobulinemia.
- To discuss established and emerging therapeutic strategies for WM.
- To highlight novel treatment modalities offering chemotherapy-free options.
Main Methods:
- Literature review of Waldenström's macroglobulinemia.
- Analysis of genetic classifications and their clinical relevance.
- Evaluation of treatment outcomes for various therapeutic agents.
Main Results:
- WM exhibits genetic heterogeneity, influencing disease classification.
- Rituximab combined with chemotherapy remains a primary treatment approach.
- Bortezomib shows efficacy as a proteasome inhibitor treatment.
- Ibrutinib, an oral Bruton's tyrosine kinase inhibitor, presents a novel chemotherapy-free therapeutic option.
Conclusions:
- Genetic insights are crucial for understanding WM subtypes.
- Established treatments like rituximab-chemotherapy combinations are effective.
- Emerging therapies, including ibrutinib, offer promising chemotherapy-free treatment avenues for WM patients.
